Most implanted nerve stimulators share an awkward truth: a wire runs from the pulse generator to the leads, and that wire is a common point of failure and infection. A Beijing company called Lingchuang Medical Valley (领创医谷) bet that it could remove the wire entirely — and investors just backed that bet with a nine-figure round.
Lingchuang (领创医谷) is not a headline brain-computer interface (脑机接口) decoder company. It is a neuromodulation specialist building what it calls a "wireless power" (无线携能) and in-body chip platform, and it is edging into brain-computer interface (脑机接口) and brain-spine interface research. Its October 2025 financing is a useful window into where Chinese capital is flowing inside the nervous-system device field — and why "wireless" is becoming the feature that separates the next generation from the last.
Key takeaways
- Lingchuang Medical Valley (领创医谷) closed a B round of about ¥200M (≈ US$27.6M / HK$218M) on 2025-10-13, led by Shunxi Fund (顺禧基金) and Beijing E-Town Investment (亦庄国投).
- The company was founded in 2016 and focuses on neuromodulation (神经调控) and pain management, with products spanning spinal, peripheral, sacral, and deep-brain stimulation.
- Its technical claim is wireless power transfer plus a self-developed in-body stimulation chip, which it says simplifies surgery and lowers power use.
- Later B+ and B++ rounds in 2026 directed capital toward closed-loop neuromodulation, brain-computer interface (脑机接口), and brain-spine interface R&D.
What the company actually makes
Neuromodulation (神经调控) is the use of electrical signals to change how the nervous system behaves — to block pain, steady a bladder, or quiet a tremor. Lingchuang (领创医谷) builds implantable stimulators across four familiar indications:
- Spinal cord stimulation (脊髓电刺激, SCS) for chronic pain.
- Peripheral nerve stimulation (周围神经电刺激, PNS) for targeted nerve pain.
- Sacral nerve stimulation (骶神经刺激, SNS) for bladder and bowel control.
- Deep brain stimulation (脑深部电刺激, DBS) for movement disorders.
The differentiator the company stresses is its "wireless power" (无线携能) architecture and a self-developed in-body chip. Traditional implanted stimulators tether a battery or pulse generator to the stimulation leads with a connecting wire; Lingchuang (领创医谷) says its approach transmits energy to the implant wirelessly and uses its own chip to keep the device small, low-power, and less invasive to place. The pitch to surgeons is a simpler operation and a better patient experience; the pitch to the market is a platform that can be extended across many indications rather than a single product.
The financing that confirmed the bet
On 2025-10-13, Lingchuang (领创医谷) disclosed a B round of about ¥200M (≈ US$27.6M / HK$218M), led by Shunxi Fund (顺禧基金) and Beijing E-Town Investment (亦庄国投), with Galaxy Innovation Capital, Guangzhou Industrial Investment, and Yizhuang Investment among the followers. Founded in 2016 and led by founder Xu Tianrui (徐天睿), the company said the proceeds would fund product-line expansion, capacity and team building, including new bases in Beijing E-Town and Keqiao, Shaoxing.
That was not the end of the money. In 2026 the company added B+ and B++ rounds — the B++ tranche in August 2026 was backed by Chuangjing Capital and a CICC Capital fund — and directed part of the new capital toward closed-loop neuromodulation (闭环神经调控), brain-computer interface (脑机接口), and brain-spine interface (脑脊接口) frontier R&D. In other words, the wireless stimulator business is the revenue base; the brain-computer interface (脑机接口) and brain-spine interface work is the option on the future.
Why wireless matters in this field
Implantable neuromodulation is a mature, competitive category dominated by large multinationals, and the usual path for a Chinese entrant is to undercut on price. Lingchuang's (领创医谷) argument is different: if you remove the wire, you change the surgery. A lead-less, wirelessly powered implant can mean a smaller incision, fewer connections to fail, and a device that is easier to revise or replace. That is a design-story advantage rather than a pure cost advantage, and design advantages are harder for incumbents to copy quickly because they touch the chip and the energy-delivery system, not just the price tag.
The risk is the opposite of romantic. Wireless power inside the body raises its own safety and reliability questions — tissue heating, energy efficiency, and long-term stability — that regulators examine closely. A "wireless" claim is only as good as the chronic-implant data behind it, and early-stage neuromodulation companies routinely spend years generating that evidence before a product is broadly reimbursed.
The China context
Lingchuang (领创医谷) fits a broader pattern in Chinese medtech: provincial industrial funds (like Beijing E-Town) backing hard-technology platforms rather than single products, and a regulatory environment that is finally giving neural-interface devices a defined path to approval. Neuromodulation (神经调控) sits one step beside brain-computer interface (脑机接口) in the same nervous-system device family, and the two are increasingly funded and regulated as neighbors.
For a company at this stage, the milestones that will matter are clinical: which of its wireless stimulators reach registration, how the closed-loop and brain-computer interface (脑机接口) research translates into investigational devices, and whether the wireless platform delivers the surgical and reliability gains it promises in real patients.
Honest limitations
This article is based on venture-data platforms, trade-press reporting (including the Science and Technology Innovation Board Daily and the China Medical Device Industry Association), and company statements. The exact "¥200M" B-round figure is reported consistently across multiple outlets but reflects disclosed-round reporting, not an audited filing; later B+ and B++ amounts are reported as "over ¥200M" combined and are not broken out here precisely. Founded-year is given as 2016 by data platforms; one trade article said 2017, a discrepancy resolved here in favor of the corroborated 2016 date. Clinical performance, regulatory status of individual products, and reimbursement are not detailed in public sources and are therefore not assessed. The brain-computer interface and brain-spine interface work is described by the company as R&D direction, not approved product, and should not be read as near-term revenue.
What readers can do now
- If you track Chinese medtech funding, treat Lingchuang's (领创医谷) wireless-power claim as the metric to verify — ask for chronic-implant reliability and heating data before assuming the "no wire" advantage is real.
- If you are a clinician or hospital buyer, watch which of its SCS/PNS/SNS/DBS products reach NMPA registration and local reimbursement lists; the platform story only matters once products are cleared and payable.
- If you follow the neural-interface field, track whether the company's closed-loop and brain-spine interface R&D produces an investigational device — that is the signal it is moving from neuromodulation into true neural interfacing.